Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
-
Clinical Benefit
Substantial
The actual benefit of this proprietary medicinal product PYLERA is substantial.
Clinical Added Value
minor
In view of the available data and bearing in mind the current development of resistance to clarithromycin by H. pyloriin France, the Committee considers that PYLERA provides a minor improvement in actual benefit (level IV) in treatment for the eradication of Helicobacter pylori.
Listen
